Skip to main content
Fig. 5 | BMC Cardiovascular Disorders

Fig. 5

From: Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study

Fig. 5

Longitudinal associations of soluble neprilysin and risk of outcomes according to LVEF after multivariable adjustment. a All-cause death and (b) the major adverse cardiovascular events. Solid purple lines represent the calculated log relative hazard in patients with left ventricular ejection fraction less than 40, and the dashed yellow line represents the log relative hazard for patients with left ventricular ejection fraction equal to or greater than 40. Shaded gray areas represent 95% confidence intervals. LVEF = left ventricular ejection fraction

Back to article page